Northwest Biotherapeutics Inc (NWBO)

Name: Northwest Biotherapeutics Inc (NWBO) annual fundamentals
Creator: TickerFacts
License: https://creativecommons.org/publicdomain/zero/1.0/

Build a valuation ↗↓ Download CSV

SEC name NORTHWEST BIOTHERAPEUTICS INC · CIK 0001072379 · OTC · Pharmaceutical Preparations

Sector Manufacturing
Incorporated DE
Fiscal year ends Dec 31

For the year ended 2025-12-31, Northwest Biotherapeutics Inc reported revenue of $1.38M. Revenue fell 0.3% from the prior annual period. Over the twelve months to 2026-06-30, revenue was $2.17M.

Key ratios (year ended 2025-12-31)

n/m

Operating margin

n/m

Net margin

-0.3%

Revenue growth (YoY)

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 10-Q (quarterly report) · 2026-08-14

Headquarters locality: Bothell · View on map

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period ended	TTM to 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Revenue	$2.17M	$1.38M	$1.38M	$1.93M	$1.68M	$1.00M	$1.29M	$2.41M	$412.0K	$336.0K	$623.0K
R&D Expense	$23.57M	$28.79M	$34.89M	$27.73M	$35.51M	$20.31M	$33.64M	$14.11M	$18.15M	$33.52M	$60.08M
Operating Income	-$50.33M	-$59.91M	-$66.51M	-$55.51M	-$67.18M	-$52.70M	-$86.61M	-$27.98M	-$41.48M	-$54.68M	-$79.27M
Depreciation & Amortization	$2.72M	$2.06M	$1.74M	$1.52M	$1.25M	$324.0K	$87.0K	$21.0K	$1.29M	$439.0K	$189.0K
EBITDA	-$47.60M	-$57.85M	-$64.76M	-$53.98M	-$65.93M	-$52.38M	-$86.52M	-$27.96M	-$40.19M	-$54.24M	-$79.08M
Net Income	-$37.73M	-$60.16M	-$83.78M	-$62.60M	-$105.03M	$179.13M	-$529.82M	-$20.81M	-$35.79M	-$73.14M	-$80.21M
EPS (Diluted)	n/a	-$0.04	-$0.07	-$0.06	-$0.10	-$0.06	-$0.73	-$0.04	n/a	n/a	n/a
Total Assets	$75.94M	$81.29M	$26.73M	$27.86M	$31.32M	$40.16M	$32.90M	$10.64M	$24.67M	$48.91M	$52.91M
Total Liabilities	$110.72M	$128.86M	$105.71M	$74.92M	$136.37M	$164.15M	$395.85M	$55.70M	$71.83M	$96.20M	$79.41M
Long-Term Debt	$51.97M	$60.04M	$62.68M	$40.79M	$21.53M	$32.40M	$14.77M	$12.72M	$16.80M	$31.43M	$31.71M
Shareholders' Equity	-$45.17M	-$60.28M	-$94.49M	-$65.77M	-$128.10M	-$123.99M	-$362.95M	-$45.05M	-$47.16M	-$67.33M	-$26.50M
Cash & Equivalents	$595.0K	$3.04M	$2.17M	$2.13M	$6.96M	$15.17M	$9.98M	$372.0K	$22.22M	$117.0K	$6.19M
Operating Cash Flow	-$48.34M	-$44.76M	-$57.02M	-$53.64M	-$52.77M	-$38.30M	-$32.09M	-$31.86M	-$34.59M	-$36.49M	-$55.65M
Capital Expenditures	$1.43M	$1.50M	$1.01M	n/a	n/a	n/a	n/a	$171.0K	n/a	n/a	n/a
Free Cash Flow	-$49.77M	-$46.27M	-$58.03M	n/a	n/a	n/a	n/a	-$32.03M	n/a	n/a	n/a
Shares Outstanding	1.67B	1.56B	1.33B	n/a	1.07B	n/a	829.60M	n/a	523.20M	328.90M	157.00M
Weighted Average Diluted Shares	n/a	1.46B	1.24B	1.12M	n/a	1.01M	n/a	564.2K	n/a	n/a	n/a
EPS (Basic)	n/a	-$0.04	-$0.07	-$0.06	-$0.10	$0.21	-$0.73	-$0.04	n/a	n/a	n/a